Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/30276
Title: Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial
Authors: Tan, Darrell H S
Raboud, Janet M
Kaul, Rupert
Grinsztejn, Beatriz
Cahn, Pedro
Walmsley, Sharon L
Affilliation: University Health Network. Toronto, Ontario, Canada.
University Health Network. Toronto, Ontario, Canada.
University Health Network. Toronto, Ontario, Canada.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundación Huesped. Buenos Aires, Argentina.
University Health Network. Toronto, Ontario, Canada.
Abstract: Although highly active antiretroviral therapy (HAART) has dramatically decreased HIV-related morbidity and mortality, the associated costs, toxicities, and resistance risks make the potential delay of HAART initiation an attractive goal. Suppression of herpes simplex virus type 2 (HSV-2) may be a novel strategy for achieving this goal because HSV-2 is associated with clinically significant increases in HIV viral load, the primary driver of HIV disease progression.
Keywords: Acyclovir
Antiviral Agents
Clinical Protocols
Disease Progression
HIV-1
Herpesvirus 2
Issue Date: 2010
Citation: TAN, D. H. S. et al. Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial. Trials, v. 11, n. 113, 2010.
DOI: 10.1186/1745-6215-11-113
ISSN: 1745-6215
Copyright: open access
Appears in Collections:INI - Artigos de Periódicos



FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.